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Abstract
Background: Intermittent preventive treatment in infants (IPTi) is a new malaria control tool. However, it is uncertain
whether IPTi works mainly through chemoprophylaxis or treatment of existing infections. Understanding the mechanism is
essential for development of replacements for sulfadoxine-pyrimethamine (SP) where it is no longer effective. This study
investigated how protection against malaria given by SP, chlorproguanil-dapsone (CD) and mefloquine (MQ), varied with
time since administration of IPTi.
Methods and Findings: A secondary analysis of data from a randomised, placebo-controlled trial in an area of high
antifolate resistance in Tanzania was conducted. IPTi using SP, CD, MQ or placebo was given to 1280 infants at 2, 3 and 9
months of age. Poisson regression with random effects to adjust for potential clustering of malaria episodes within children
was used to calculate incidence rate ratios for clinical malaria in defined time strata following IPTi. The short-acting
antimalarial CD gave no protection against clinical malaria, whereas long-acting MQ gave two months of substantial
protection (protective efficacy (PE) 73.1% (95% CI: 23.9, 90.5) and 73.3% (95% CI: 0, 92.9) in the first and second month
respectively). SP gave some protection in the first month after treatment (PE 64.5% (95% CI: 10.6, 85.9)) although it did not
reduce the incidence of malaria up to 12 months of age. There was no evidence of either long-term protection or increased
risk of malaria for any of the regimens.
Conclusion: Post-treatment chemoprophylaxis appears to be the main mechanism by which IPTi protects children against
malaria. Long-acting antimalarials are therefore likely to be the most effective drugs for IPTi, but as monotherapies could be
vulnerable to development of drug resistance. Due to concerns about tolerability, the mefloquine formulation used in this
study is not suitable for IPTi. Further investigation of combinations of long-acting antimalarials for IPTi is needed.
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Introduction
Intermittent preventive treatment in infants (IPTi) is a new
control strategy for reducing the malaria burden in endemic
countries of sub-Saharan Africa where transmission of malaria is
high and malaria is an important cause of mortality and morbidity
in infants. There is now sufficient evidence that three courses of
sulfadoxine-pyrimethamine (SP) IPTi has a protective efficacy of
20–30% against clinical malaria in the first year of life; therefore
SP-IPTi may be adopted as a policy in some African countries
[1,2]. However, widespread and escalating resistance to SP
remains a concern and it is unlikely that SP-IPTi will remain
effective in areas where there is high prevalence of SP resistance,
as has been the case for IPT in pregnant women [3,4].
Consequently, other drugs need to be developed urgently for IPTi.
Although the first IPTi study found a suggestion of sustained
protection [5,6], subsequent SP-IPTi trials have established that in
most circumstances, protection is likely to be attributable to the
direct effect of the drugs used [7–11]. Nevertheless, some
uncertainty about the precise mode of action of IPTi remains, in
particular, the relative importance of clearing existing parasitae-
mia compared to post-treatment prophylaxis against new
infections is not certain, and may vary in different epidemiological
settings [12]. Two studies of the duration of protection against
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malaria after IPTi using SP have suggested that post-treatment
prophylaxis may be the main protective mechanism [13,14], but
this is not yet certain, and it is unclear whether this will be the case
for IPTi regimens other than SP.
To investigate these issues, an individually randomised, placebo-
controlled trial of SP and two alternative regimens (chlorprogua-
nil-dapsone, CD and mefloquine, MQ) was undertaken in an area
of high SP resistance in Tanzania [15]. This trial sought to identify
whether SP retained its efficacy for IPTi despite a high prevalence
of antifolate resistance, whether a short-acting antimalarial such as
CD (terminal elimination half-life ,40 hours [16]) could be used
effectively for IPTi and whether a long-acting antimalarial such as
MQ (half-life 2–3 weeks [17]) would be more effective. The trial
found that neither SP nor CD provided any protection either
during the intervention period (2–11 months) or between 12 and
23 months of age. MQ was found to provide a high level of
protection between the ages 2–11 months (PE 38.1% (95% CI
11.8, 56.5), but concerns about its tolerability in infants may make
it unsuitable for IPTi in its current formulation.
It could be informative to investigate how protective efficacy in
the above study varies with time since treatment. While it is possible
that the finding of no benefit overall for SP or CD could mean that
there is genuinely no benefit at any time, it is also possible that there
is either a small benefit initially after treatment which is too small to
remain detectable over the whole of infancy. Alternatively, it may be
that an initial benefit of treatment is cancelled out by a subsequent
increased risk of clinical malaria, either through loss of premunition
[18,19], or due to suppressed drug resistant parasites surviving
treatment and recrudescing at a later stage [20].
The purpose of the present study was therefore to investigate
how the protective efficacy of the three drug regimens used in the
above trial changed with time since treatment, and thus clarify the
mechanism of protection given by IPTi.
Methods
Trial Background
This study uses data from the Kilimanjaro IPTi Drug Options
Trial, described in detail elsewhere [15]. The protocol for this trial is
available as supporting information; see Protocol S1. The trial was
registered as a randomised clinical trial with the National Institute
for Health clinical trials registry (www.clinicaltrials.gov identifier:
NCT00158574), and was approved by the Ethics Review Board of
the National Institute for Medical Research of Tanzania and the
London School of Hygiene and Tropical Medicine. Briefly, a
double-blind, individually randomised, placebo-controlled trial of
IPTi using SP, CD and MQ was undertaken in two districts in
Tanzania with a high prevalence of SP resistance. Full treatment
doses of the study drugs were given to children enrolled in the trial at
the time of the second diphtheria-pertussis-tetanus/polio vaccine
(DPT/polio 2), DPT/polio 3 and measles vaccinations at
approximately 2, 3 and 9 months of age. The separate IPT rounds
are referred to in this paper as IPT1, IPT2 and IPT3. Children were
followed-up until two years of age for incidence of the primary
outcome of clinical malaria (temperature $37.5uC or history of
fever within 48 hours plus parasitaemia of any density).
The analyses presented here use only data from the moderate
transmission site in Korogwe, Tanga Region, Tanzania. Bødker
et al. [21] reported an entomological inoculation rate (EIR) of nearly
100 infectious bites per year in the Korogwe lowlands, though it is
thought that transmission has since declined as it has in other
regions of Tanzania [22] and South and East Africa [23]. Recently,
an in vivo efficacy study of SP in this region showed a day 28
adequate clinical and parasitological response of only 18% [24].
Data Analysis
Children who had received and successfully swallowed a given
round of IPT (IPT1, IPT2 or IPT3) were included in the analysis.
The endpoint was clinical malaria, as defined above, detected
passively at one of the study clinics. Time at risk was calculated
from time of IPT treatment until completion of five months (150
days) of follow-up, receipt of a subsequent dose of IPT or exit from
the study (emigration, death, refusal or exclusion), whichever
occurred first. As in the main trial analysis, children who had a
malaria episode or who were treated with an antimalarial had 21
days removed from the person time at risk. To enable month
specific estimates of the protective efficacy by time since treatment,
follow-up time was stratified by month (30 days) since treatment
using lexis expansion [25].
Poisson regression was used to calculate incidence rate ratios for
clinical malaria, allowing multiple episodes of malaria per child.
To adjust for potential clustering of malaria episodes within
children, Poisson regression models with gamma distributed
random effects were used. Multivariate models were built using
an additive step-wise approach, using the likelihood ratio test to
compare models and aiming for the simplest model that
adequately explained the data. Since the principal interest of this
study was the interaction between intervention group and time
since treatment, this interaction was modelled first. Covariates
known to be associated with the incidence of malaria in this
population from the main trial were then added to the models
(ownership of an insecticide treated net, rural residence and
distance of residence from the nearest health facility).
To explore the changes in protective efficacy against clinical
malaria over time, malaria incidence rate ratios for SP, CD and
MQ versus placebo by month since IPT were calculated.
Protective efficacy and its 95% confidence interval was then
calculated as 1-rate ratio. To obtain more precise estimates of
protective efficacy over time, a summary analysis was then
performed combining time at risk and malaria episodes following
all three IPT rounds into a single analysis that related malaria
incidence to time since most recent IPT. To account for possible
differences in efficacy between separate IPT rounds, the IPT
round from which time at risk and incidence was taken was tested
for inclusion in the multivariate regression models as an
interaction term with treatment group and as a covariate.
Results
In the analysis of the clinical trial, IPTi with MQ was shown to
provide a protective efficacy against clinical malaria of 38.1%
(95% CI 11.8, 56.5) in infants aged 2–11 months of age. There was
no statistically significant protective effect from SP 26.7% (245.9,
22.0) or CD 10.8% (224.6, 36.1) during infancy [15].
It was not possible to calculate protective efficacy by month
after IPT1, since most children received IPT2 one month later
(75% within 28 days and 95% within 42 days of IPT1) and
incidence of malaria in the placebo group in this period was very
low (table 1). Inclusion of treatment round number in the
regression models did not improve the fit of the model to the
data for the multi-round analyses of either SP or CD but it was
included as a covariate in the model for the multi-round analysis of
mefloquine protective efficacy.
Sulfadoxine-Pyrimethamine
There was no statistically significant evidence that SP gave any
protection in any specific month after IPT2 (Table 2 and Figure 1).
However, the confidence intervals around these estimates are
wide, reflecting the low incidence rate in these young children.
Duration of IPTi Protection
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There was statistically significant evidence of considerable
protection in the first month after IPT3 (protective efficacy (PE)
87.5% (95% CI: 42.4, 97.3); p = 0.008) but no further protection
after this time. In the summary analysis of all rounds of IPT
combined, there was again evidence of protection in the first
month after treatment, (PE 64.5% (10.6, 85.9); p = 0.028), but no
evidence of protection beyond this time. There was a suggestion of
increased incidence in children given SP compared to those given
placebo in some months, but this was not statistically significant.
Chlorproguanil-Dapsone
There was no evidence of protection from CD in most months
after treatment (Table 2 and Figure 2). There was a suggestion that
CD gave some protection during the third month after IPT2 (PE
67.4% (23.6, 89.7); p = 0.057) and in the third month in the
summary analysis of all 3 IPT rounds (PE 59.4% (8.0, 82.0);
p = 0.031). Consistent with the finding during the whole trial
period, there was no evidence of any protective benefit of IPT with
CD at any other time.
Mefloquine
The point estimates of protective efficacy suggested some
protection in the two months following IPT2, but the confidence
interval overlaps unity (Table 2 and Figure 3). Beyond the 2 month
period there was no evidence of any protection or any detrimental
effect of IPT2. There was strong evidence of protection in the first
month after IPT3 (PE 80.1% (27.3, 94.5); p = 0.014, and
suggestion of protection in the second month that was not
statistically significant (PE 69.7% (255.2, 94.1), p = 0.152).
In the summary analysis of all 3 IPT rounds, there was strong
evidence of a high level of protection in the first month (PE 73.1%
(23.9, 90.5); p = 0.013). The point estimate of protective efficacy
was similarly high in the second month, but this was only of
borderline statistical significance (PE 73.3% (0, 92.9); p = 0.050).
There was a suggestion of protection in the third month but this
was not statistically significant. There is thus no strong evidence of
any benefit or detrimental effect in months three, four or five after
IPT with MQ.
Discussion
Principal Findings
Mefloquine provided a high level of protection against clinical
malaria in the first two months after IPTi, consistent with its
extended plasma half-life and its presumed therapeutic efficacy in
Africa [17,26]. There was no increased risk of malaria once
protection from MQ had waned, suggesting that there is no
detrimental effect in the post-IPT period.
SP provided some protection against clinical malaria in the first
month after IPT, despite the high prevalence of antifolate
resistance in the study site [24]. There was no statistically
significant evidence of either a protective or detrimental effect in
any period beyond the first month, though the point estimate and
confidence interval in the second month were consistent with a
modest detrimental effect.
Chlorproguanil-dapsone provided little protection against
clinical malaria compared to placebo. While there was a
suggestion of some protection in the third month after IPT,
largely due to apparent protection after IPT2, we consider this
likely to be a chance finding given the borderline statistical
significance and the lack of a plausible biological mechanism for
protection to be delayed to such a specific and finite window after
treatment. Chlorproguanil-dapsone was shown to be effective in
treating acute malaria episodes that had failed treatment with SP
in Tanzania [27] and SP-resistance was associated with failure of
treatment with SP but not CD in Malawi [28]. It therefore appears
likely that the poor performance of CD as an IPT regimen is due
to its short half-life.
Table 2. Protective efficacy against clinical malaria by month after IPTi.
IPT2 IPT3 All IPT rounds
Month Protective efficacy (95% CI) Protective efficacy (95% CI) Protective efficacy (95% CI)
SP 1 17 (2524.1, 89) 87.5 (42.4, 97.3) 64.5 (10.6, 85.9)
2 2148.7 (2900.7, 38.2) 247.8 (2340.8, 50.4) 270.8 (2285.5, 24.4)
3 52.7 (235.4, 83.4) 210 (2190.6, 58.4) 31.8 (236.2, 65.8)
4 244.7 (2243.9, 39.1) 2143 (2541, 7.9) 270.9 (2219.6, 8.6)
5 221 (2244.4, 57.5) 33 (2100.5, 77.6) 12.6 (282.7, 58.2)
CD 1 8.2 (2591.9, 87.8) 54.5 (225.6, 83.5) 28.9 (255.5, 67.5)
2 8 (2391.3, 82.8) 218.3 (2286.8, 63.8) 8 (2134.9, 63.9)
3 67.4 (23.6, 89.7) 48.6 (275.3, 84.9) 59.4 (8, 82)
4 34.8 (276, 75.8) 14.3 (2183.5, 74.1) 23.5 (259.6, 63.4)
5 220.8 (2251, 58.4) 39.9 (289.4, 80.9) 7.5 (294, 55.9)
MQ 1 56.5 (2415.5, 96.3) 80.1 (27.6, 94.5) 73.1 (23.9, 90.5)
2 72.2 (2188.8, 97.3) 69.7 (255.2, 94.1) 73.3 (0, 92.9)
3 33.1 (292.4, 76.7) 34.2 (294.4, 77.7) 36.1 (230.9, 68.8)
4 10.7 (2141.5, 67) 288 (2405.8, 30.1) 225.6 (2144.7, 35.5)
5 63.1 (258, 91.4) 238.1 (2248.7, 45.3) 13.7 (283, 59.3)
Estimates of protective efficacy against clinical malaria, calculated as (1- rate ratio of active treatment [SP, CD or MQ] vs. placebo). All regression models were adjusted
for the covariates ITN use, rural residence and distance from nearest health facility. Mefloquine (All IPT rounds) was also adjusted for IPT round. Most children exited
follow-up after the administration of IPT1 around one month later, when they received IPT2 at approximately 3 months of age. For this reason this analysis was not
possible for follow-up after IPT1. Abbreviations: CI, confidence interval; SP, sulfadoxine-pyrimethamine; CD, chlorproguanil-dapsone; MQ, mefloquine.
doi:10.1371/journal.pone.0009467.t002
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Limitations
Due to the relatively low incidence rate of clinical malaria in this
study population, estimates of the intervention effect are less
precise than would be ideal for this type of analysis, and the time-
stratified analyses are likely to be underpowered to detect effects in
specific time strata. This is particularly the case when examining
the protective efficacy of IPT1 and IPT2. The low incidence rate
also limits the minimum size of time strata for which sensibly
precise estimates of protective efficacy can be calculated to around
one month. The analytical approach includes multiple compar-
isons and thus it is possible some spurious low p-values may have
appeared due to chance. However, in the present analysis, the
directions of trends can still be seen, which combined with
understanding of the pharmacodynamics of the antimalarials
allows a biologically plausible interpretation to be made. With a
larger trial or a higher incidence rate of malaria, it would have
been possible to stratify follow-up more finely to get a more
detailed picture of how protection varies over time, as was possible
in a similar analysis of the Navrongo IPTi trial [13]. It would also
be possible to set lower thresholds for statistical significance in
order to better exclude the role of chance.
To assess if our findings could have been affected by the
decision to stratify follow-up time by month, the analyses were
repeated with different sized time strata. This did not alter the
estimate of duration of protection or the interpretation (data not
shown). We did not find any evidence of interaction between IPTi
drug group and IPTi round (i.e. there was no suggestion that
efficacy of IPTi compared to placebo varied between the different
rounds), but it would be preferable to have greater precision to
look at separate rounds in isolation.
Interpretation
Short-acting antimalarials are unlikely to be a suitable choice for
intermittent preventive treatment in infants. Longer-acting
antimalarials with a duration of action similar to that of
mefloquine and SP are likely to be more efficacious, since they
would provide a substantial period of post-treatment prophylaxis.
However, the mefloquine formulation used in this trial is not likely
to be suitable for IPTi because it is poorly tolerated [15], and the
usefulness of SP in areas where resistance is high may be severely
limited. The protective efficacy of SP within the first month seen
here (64.5% (10.6, 85.9)) is comparable with that seen in a
previous study in Ghana, where protection against malaria in the
first month was 75.2% (66, 82) [13], but unlike in Ghana, after one
month there was no evidence of any further protection, and no
overall benefit of IPTi in infancy [15].
The finding of protection limited to a shorter period
immediately after IPTi with SP suggests that malaria episodes
are only prevented when plasma concentrations of both
sulfadoxine and pyrimethamine are greatest and the two
components act in synergy; this period may last for 15 days for
antifolate resistant parasites [29]. Shortened post-treatment
prophylaxis is known to be a consequence of drug resistance
Figure 1. Protective efficacy of SP against clinical malaria.
Protective efficacy (1- rate ratio vs. placebo) is shown by month since
treatment. Y-axes for IPT2 and IPT3 graphs are truncated at -300, for full
extent of confidence interval see table 2.
doi:10.1371/journal.pone.0009467.g001
Figure 2. Protective efficacy of CD against clinical malaria.
Protective efficacy (1- rate ratio vs. placebo) is shown by month since
treatment. Y-axes for IPT2 and IPT3 graphs are truncated at -150, for full
extent of confidence interval see table 2.
doi:10.1371/journal.pone.0009467.g002
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[30], and indeed protection from SP was shorter than in other
studies of SP-IPTi in areas with lower SP resistance [13,14].The
suggestion of slightly increased incidence of malaria in the second
month after SP-IPTi, combined with our knowledge of resistance
patterns in the study site and the overall lack of any protection in
infancy overall is consistent with the hypothesis that SP was not able
to completely eliminate highly resistant parasites. We speculate that
when drug levels waned sufficiently, previously suppressed infec-
tions then increased in density and caused clinical attacks of malaria.
Measuring protective efficacy in a short period after an IPTi course
(e.g. the first month) could be misleading since it would miss
recrudescence that was delayed beyond this time by a long-acting
but ultimately ineffective antimalarial. Similar arguments have
previously been made for assessment of therapeutic efficacy [31].
The overall protective efficacy of mefloquine up to 12 months of
age in this trial was 38.1% (95% CI: 11.8, 56.5), which compares
favourably with most of the trials of SP [7–11]. Protection appears
to be concentrated in the first two months after the dose, making
the duration of protection slightly longer than in infants given SP
[13,14]. Since mefloquine has a longer half-life than SP (2 to 3
weeks versus 7 days for sulfadoxine and 3 days for pyrimethamine
[17,20,29,32]), a slightly longer period of post-treatment prophy-
laxis would be expected. In a separate study of the efficacy of
mefloquine for the treatment of asymptomatic parasitaemia
completed in 24 month old children, we found that just below
half of 24 month old children still had detectable levels of
mefloquine 56 days after treatment (data not shown). These
findings are therefore coherent, and consistent with the idea that
the benefits of IPTi are restricted to the direct pharmacodynamics
of the drugs involved.
If long-acting drugs offer the best protection when used for
IPTi, this raises an immediate dilemma. Slowly eliminated
antimalarial drugs may be most prone to development of drug
resistance [33]. It is not clear how this problem can best be tackled.
One solution could be the combination of long acting drugs with
similar pharmacokinetic profiles since these could protect each
other from selection of resistant genotypes as they are progressively
eliminated [34]. However, this has not been adequately investi-
gated in practice, and there are few candidate antimalarials
currently available for this role. Single dose regimens for IPT
would be preferable to a course given over several days. Safety will
be a particularly important consideration when developing future
IPTi regimens, since many children who receive IPT will be
healthy at the time they are treated. Other studies undertaken by
the IPTi Consortium will report on the safety profile of the existing
IPTi drugs.
Conclusion
Mefloquine, the most efficacious regimen in this IPTi trial,
protected children by giving a substantial period of post-treatment
prophylaxis. SP provided protection against clinical malaria for
approximately one month, but it appears that some malaria
attacks were simply delayed until the following month once drug
concentrations had waned. Given concerns about possible side-
effects and tolerability of mefloquine, and exacerbation of drug
resistance, novel combinations of long-acting antimalarials should
be investigated for use in IPTi.
Supporting Information
Protocol S1 Trial Protocol
Found at: doi:10.1371/journal.pone.0009467.s001 (1.08 MB
DOC)
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